Neurotech Completes $10.0 Million Capital Raise

Highlights:

- **Single tranche share Placement completed with strong results in the Phase II/III autism spectrum disorder (ASD) clinical trial and the Rett Syndrome Phase I/II clinical trial meeting its primary endpoint**
- **Binding commitments for a $10.0 million Placement with support from existing and new institutional, professional and sophisticated Australian and overseas investors**
- **Capital raised to be used to accelerate registration-directed activities, fund further clinical trials as required and manufacturing expansion**
- **Full results of the Phase I/II Rett Syndrome clinical trial including secondary endpoint analysis and safety/tolerability data expected in 2-4 weeks**

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, is pleased to announce a successful $10.0 million placement (**Placement**) to institutional, professional and sophisticated Australian and overseas investors.

Dr Thomas Duthy, Executive Director of Neurotech said *"On behalf of the Board of Directors of Neurotech, we thank investors for their strong support of the Placement, and welcome our new institutional investors, following the delivery of outstanding clinical results in ASD along with top-line Rett Syndrome data where we met the primary endpoint. Our group corporate strategy has expressly focussed on NTI164 clinical development in paediatric neurological disorders with persistent or progressive neuroinflammation. This has resulted in all our clinical trials launched and recruited over the last 12 months delivering statistically significant and clinically meaningful results in three very challenging neurological disorders where effective treatments are lacking, namely ASD, Rett Syndrome and PANDAS/PANS with the latter two disorder classified as rare or orphan diseases*[1]*."*

Dr Duthy continued *"We are very much looking forward to delivering to our investors the full results of our 14 patient Phase I/II Rett Syndrome clinical trial which will provide further analysis and interpretation of our initial primary endpoint result announced today. In addition, important secondary endpoints and safety/tolerability data will be available, which will permit Neurotech to examine these results in the context of the implied hurdle rates for regulatory approval in the United States given the FDA approval of DAYBUE™ (trofinetide) in March 2023 using similar measures of efficacy and safety. We intend to deploy our new capital into initiatives that accelerate our commercial and clinical development of this safe and effective therapy for children suffering the dire effects of these neurological disorders."*

NTIASD2 was a randomised, double-blind, placebo-controlled, Phase II/III clinical trial that recruited 54 patients with ASD to determine the efficacy and safety of NTI164 versus placebo. The results showed a statistically significant and clinically meaningful change in the gold standard clinical measure Clinical Global Impression - Severity of Illness (CGI-S): -1.65 treatment effect ($p<0.001$). A decrease in CGI-S score indicates improvement. In addition, NTI164 conferred significant benefits versus placebo across key secondary endpoints examining adaptive behaviour improvements (Vineland™-3) ($p=0.024$), social responsiveness ($p=0.028$), CGI-improvement (CGI-I) ($p<0.001$).

[1] Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS)

The NTIRTT1 Rett Syndrome clinical trial was designed to examine safety, and gold standard measures of clinical symptoms associated with Rett Syndrome at 12 weeks of daily oral NTI164 treatment compared to baseline measures in 14 paediatric female patients. Initial primary endpoint analysis has shown a statistically significant difference (improvement) in CGI-I at 12 weeks versus baseline measures; mean difference of -0.3 (p=0.04). A decrease in CGI-I score indicates improvement.

Placement

The Company has received binding commitments from institutional, professional and sophisticated investors totalling $10,000,000 for the issue of 100.0 million new fully paid ordinary shares (**New Shares**). The issue price under the Placement is $0.10 per New Share, representing a 4.8% discount to the last closing price of $0.105 immediately prior to the Company's trading halt for purposes of the clinical results and capital raise, a 3.5% discount to the 5 day volume weighted average price (**VWAP**) of $0.1036 and a 4.6% discount to the 15 day VWAP of $0.1049.

In addition, each Placement participant will be entitled to subscribe for 1 free attaching option (**New Option**) for every 2 New Shares subscribed for under the Placement, representing of 50.0 million New Options. The New Options will have a two year expiry from date of issuance and a strike price of $0.16.

The Company intends to issue the New Shares on or around 24 April 2024. 30,000,000 New Shares and 50,000,000 New Options will be issued under the Company's issue capacity pursuant to ASX Listing Rule 7.1, with the remaining 70,000,000 New Shares being issued under the Company's placement capacity pursuant to ASX Listing Rule 7.1A. Refer to the Appendix 3B lodged by the Company today for further disclosures in connection with the Placement.

Use of Funds

Funds raised under the placement will be applied to the Company's further clinical trials (as required), regulatory development work, IND enabling toxicology initiatives, product manufacturing and expansion, costs in relation to the Placement and general working capital.

Authority
This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information
Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI)) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric

Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit http://www.neurotechinternational.com.

About NTI164

NTI164 is a proprietary drug formulation derived from a unique cannabis strain with low THC (M<0.3%) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN. NTI164 has been exclusively licenced for neurological applications globally. Pre-clinical studies have demonstrated a potent anti-proliferative, anti-oxidative, anti-inflammatory and neuro-protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.